Inotersen (ISIS-420915) sodium is a 2′-O-methoxyethyl-modified antisense oligonucleotide. Inotersen sodium inhibits the production of transthyretin (TTR) protein by targeting the TTR RNA transcript and reduces the levels of the TTR transcript. Inotersen sodium can be used for the research of hereditary TTR amyloidosis polyneuropathy.

Inotersen sodium (0.16-20 μM; 16 h) dose-dependently reduces TTR mRNA levels in HepG2 cells[1].

Inotersen sodium (10-100 mg/kg; s.c. twice a week for 4 weeks) reduces the plasma TTR protein by >80% in transgenic mice bearing the Ile84Ser human TTR mutant[1].

1432726-13-0

ISIS-420915 sodium;Inotersen sodium

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years